What is RuiYi?
RuiYi is a specialized biopharmaceutical company focused on the discovery and development of novel antibody therapeutics. The firm distinguishes itself through its proprietary iCAPS (intramembranous Conformation Antigen Presenting System) platform, which enables the discovery of functional antibodies targeting G protein-coupled receptors (GPCRs). These targets, while validated by small molecules, have historically proven difficult to drug successfully. By focusing on first-in-class and best-in-class antibody therapeutics, RuiYi addresses critical gaps in the treatment of fibrotic and metabolic diseases, including nonalcoholic steatohepatitis (NASH). The company's strategic positioning at the intersection of advanced protein engineering and high-unmet-need therapeutic areas places it as a significant player in the modern biotech landscape.
How much funding has RuiYi raised?
RuiYi has raised a total of $32M across 3 funding rounds:
Series A
$13M
Series B
$15M
Debt
$4M
Series A (2009): $13M with participation from SR One, Versant Ventures, Merck Serono Ventures, and Apposite Capital
Series B (2012): $15M led by SR One, Versant Ventures, Aravis, Merck Serono Ventures, Apposite Capital, and 5AM Ventures
Debt (2014): $4M supported by Silicon Valley Bank
Key Investors in RuiYi
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world with over $5.5 billion under management.
5AM Ventures
5AM Ventures is a life science-focused venture capital firm that backs early-stage biotech and healthcare innovators, partnering closely with founders to shape companies.
What's next for RuiYi?
With the support of its recent strategic investment, RuiYi is well-positioned to accelerate the clinical development of its lead candidates, including RYI-018. The company's forward-looking strategy centers on leveraging its iCAPS platform to expand its pipeline of antibody therapeutics, potentially unlocking new treatment modalities for complex diseases. As the firm continues to mature, the focus will likely shift toward clinical trial milestones and potential partnerships with larger pharmaceutical entities to facilitate the commercialization of its innovative portfolio. The combination of robust scientific discovery and sustained financial backing provides a solid foundation for RuiYi to maintain its competitive edge in the rapidly evolving biotechnology sector.
See full RuiYi company page
